Literature DB >> 21917774

Levodopa toxicity and Parkinson disease: still a need for equipoise.

C Warren Olanow, Jose A Obeso.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21917774     DOI： 10.1212/WNL.0b013e318232ac0a

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  12 in total

1.  IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.

Authors:  Talene A Yacoubian
Journal:  Neurodegener Dis Manag       Date:  2013-04-01

2.  Levodopa treatment in Parkinson's disease: earlier or later?

Authors:  Federico Paolini Paoletti; Nicola Tambasco; Lucilla Parnetti
Journal:  Ann Transl Med       Date:  2019-09

3.  1,25-dyhydroxyvitamin D3 attenuates L-DOPA-induced neurotoxicity in neural stem cells.

Authors:  Wooyoung Jang; Hyun-Hee Park; Kyu-Yong Lee; Young Joo Lee; Hee-Tae Kim; Seong-Ho Koh
Journal:  Mol Neurobiol       Date:  2014-08-08       Impact factor: 5.590

Review 4.  MRI reveals brain abnormalities in drug-naive Parkinson's disease.

Authors:  Peggy J Planetta; Nikolaus R McFarland; Michael S Okun; David E Vaillancourt
Journal:  Exerc Sport Sci Rev       Date:  2014-01       Impact factor: 6.230

Review 5.  Experimental Intrastriatal Applications of Botulinum Neurotoxin-A: A Review.

Authors:  Alexander Hawlitschka; Andreas Wree
Journal:  Int J Mol Sci       Date:  2018-05-07       Impact factor: 5.923

Review 6.  Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review.

Authors:  Khalid Orayj; Emma Lane
Journal:  Parkinsons Dis       Date:  2019-11-03

7.  Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration.

Authors:  Vignayanandam Ravindernath Muddapu; V Srinivasa Chakravarthy
Journal:  Sci Rep       Date:  2021-01-18       Impact factor: 4.379

8.  Dopaminergic Therapy Modulates Cortical Perfusion in Parkinson Disease With and Without Dementia According to Arterial Spin Labeled Perfusion Magnetic Resonance Imaging.

Authors:  Wei-Che Lin; Pei-Chin Chen; Yung-Cheng Huang; Nai-Wen Tsai; Hsiu-Ling Chen; Hung-Chen Wang; Tsu-Kung Lin; Kun-Hsien Chou; Meng-Hsiang Chen; Yi-Wen Chen; Cheng-Hsien Lu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

9.  Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.

Authors:  Constant V M Verschuur; S R Suwijn; B Post; M Dijkgraaf; B R Bloem; J J van Hilten; T van Laar; G Tissingh; G Deuschl; A E Lang; R J de Haan; R M A de Bie
Journal:  BMC Neurol       Date:  2015-11-19       Impact factor: 2.474

10.  Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson's Disease.

Authors:  Karsten Mueller; Robert Jech; Tommaso Ballarini; Štefan Holiga; Filip Růžička; Fabian A Piecha; Harald E Möller; Josef Vymazal; Evžen Růžička; Matthias L Schroeter
Journal:  Cerebellum       Date:  2019-04       Impact factor: 3.847
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.